Literature DB >> 2498937

Hyperthermia induced by m-CPP in the rat and its modification by antidepressant treatments.

K M Wozniak1, C S Aulakh, J L Hill, D L Murphy.   

Abstract

Administration of the serotonin agonist m-chlorophenylpiperazine to rats produced a dose-related hyperthermia. Pretreatment with the serotonin receptor antagonist metergoline totally abolished this response, whereas similar treatment with haloperidol, phenoxybenzamine, naloxone, clonidine, pindolol, propranolol, methiotepin, and ritanserin was ineffective. In studies investigating the modification of the response by antidepressant treatments both acute (3 day) and chronic (22 day) administration of the MAO inhibitor clorgyline, as well as the tricyclics clomipramine and imipramine, attenuated the hyperthermic response to m-CPP. These findings are discussed with regard to the specificity of m-CPP-induced hyperthermia and its subsequent modification by antidepressant treatments, in order to evaluate this model's use as a probe for assessment of the serotonergic system.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498937     DOI: 10.1007/bf00442262

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  38 in total

1.  The effect of drugs acting on dopamine receptors on the body temperature of the rat.

Authors:  Z L Kruk
Journal:  Life Sci I       Date:  1972-09-15

2.  Long-term antidepressant treatment decreases spiroperidol-labeled serotonin receptor binding.

Authors:  S J Peroutka; S H Snyder
Journal:  Science       Date:  1980-10-03       Impact factor: 47.728

3.  Influence of adrenocorticotropin hormone and yohimbine on antidepressant-induced declines in rat brain neurotransmitter receptor binding and function.

Authors:  D A Kendall; R Duman; J Slopis; S J Enna
Journal:  J Pharmacol Exp Ther       Date:  1982-09       Impact factor: 4.030

4.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

6.  Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.

Authors:  J E Leysen; W Gommeren; P Van Gompel; J Wynants; P F Janssen; P M Laduron
Journal:  Mol Pharmacol       Date:  1985-06       Impact factor: 4.436

7.  Neuroendocrine and behavioral effects of m-chlorophenylpiperazine administration in rhesus monkeys.

Authors:  J A Aloi; T R Insel; E A Mueller; D L Murphy
Journal:  Life Sci       Date:  1984-04-02       Impact factor: 5.037

8.  Serotonin-releasing effects of substituted piperazines in vitro.

Authors:  D J Pettibone; M Williams
Journal:  Biochem Pharmacol       Date:  1984-05-01       Impact factor: 5.858

9.  Amitriptyline and femoxetine, but not clomipramine or citalopram, antagonize hyperthermia induced by directly acting 5-hydroxytryptamine-like drugs in heat adapted rats.

Authors:  L Pawłowski
Journal:  J Pharm Pharmacol       Date:  1984-03       Impact factor: 3.765

10.  Long-term imipramine treatment enhances locomotor and food intake suppressant effects of m-chlorophenylpiperazine in rats.

Authors:  C S Aulakh; R M Cohen; J L Hill; D L Murphy; J Zohar
Journal:  Br J Pharmacol       Date:  1987-08       Impact factor: 8.739

View more
  9 in total

1.  5-HT1C receptors in the serotonergic control of periaqueductal gray induced aversion in rats.

Authors:  F Jenck; C L Broekkamp; A M Van Delft
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

2.  (+/-)-1-(2,5-Dimethoxy-4-ethylthiophenyl)-2-aminopropane (ALEPH-2), a novel putative anxiolytic agent lacking affinity for benzodiazepine sites and serotonin-1A receptors.

Authors:  M Reyes-Parada; C Scorza; V Romero; R Silveira; J H Medina; D Andrus; D E Nichols; B K Cassels
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

3.  Evidence that m-chlorophenylpiperazine-induced hyperthermia in rats is mediated by stimulation of 5-HT2C receptors.

Authors:  P Mazzola-Pomietto; C S Aulakh; K M Wozniak; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1996-02       Impact factor: 4.530

4.  Ritanserin attenuates anorectic, endocrine and thermic responses to d-fenfluramine in human volunteers.

Authors:  E M Goodall; P J Cowen; M Franklin; T Silverstone
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

5.  Evidence that 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced hyperthermia in rats is mediated by stimulation of 5-HT2A receptors.

Authors:  P Mazzola-Pomietto; C S Aulakh; K M Wozniak; J L Hill; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1995-01       Impact factor: 4.530

6.  Chronic treatment with meta-chlorophenylpiperazine (m-CPP) alters behavioral and cerebral metabolic responses to the serotonin agonists m-CPP and quipazine but not 8-hydroxy-2(di-N-propylamino)tetralin.

Authors:  U Freo; H W Holloway; N H Greig; T T Soncrant
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

7.  Serotonergic modulation of the rat pup ultrasonic isolation call: studies with 5HT1 and 5HT2 subtype-selective agonists and antagonists.

Authors:  J T Winslow; T R Insel
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

8.  The tricyclic antidepressant clomipramine dose-dependently reduces regional cerebral metabolic rates for glucose in awake rats.

Authors:  U Freo; P Pietrini; M Dam; G Pizzolato; L Battistin
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

Review 9.  5-HT Receptors and Temperature Homeostasis.

Authors:  Irina P Voronova
Journal:  Biomolecules       Date:  2021-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.